SeaStar Medical — Third Quarter 2026 Earnings Summary

SeaStar Medical Holding Corporation reported net revenue of $635,000 for the third quarter of 2026, representing a 247% increase compared to the same period in 2025, driven by the adoption of its QUELIMMUNE therapy for pediatric acute kidney injury. The company achieved nearly 75% enrollment in its NEUTRALIZE-AKI pivotal clinical trial for adult patients and received Breakthrough Device Designation from the FDA for treating hyperinflammation in adults with sepsis. During the quarter, the company reported a net loss of $4.5 million, or $1.03 per share, while maintaining cash reserves of $4.0 million as of September 30, 2026.